about
Dermokine-β impairs ERK signaling through direct binding to GRP78Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.Effects of bisphosphonate administration on the bone mass in immune thrombocytopenic purpura patients under treatment with steroids.A crucial role of L-selectin in C protein-induced experimental polymyositis in mice.Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome.Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study.B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosisHuman Leukocyte Antigen and Systemic Sclerosis in Japanese: The Sign of the Four Independent Protective Alleles, DRB1*13:02, DRB1*14:06, DQB1*03:01, and DPB1*02:01.Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies.Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.Survey of single-nucleotide polymorphisms in the gene encoding human deoxyribonuclease I-like 2 producing loss of function potentially implicated in the pathogenesis of parakeratosis.The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis.CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma.Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model.The differential role of L-selectin and ICAM-1 in Th1-type and Th2-type contact hypersensitivity.The roles of chemokines in the development of systemic sclerosis.CD19, a response regulator of B lymphocytes, regulates wound healing through hyaluronan-induced TLR4 signaling.Dermoscopy findings of nail fold capillaries in connective tissue diseases.Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines.Low zone tolerance requires ICAM-1 expression to limit contact hypersensitivity elicitation.Biomarkers in systemic sclerosis: Their potential to predict clinical courses.CD34-positive infantile myofibromatosis: Case report and review of hemangiopericytoma-like pattern tumors.Reduced hypoxia risk in a systemic sclerosis patient with interstitial lung disease after long-term pulmonary rehabilitation.A Case of Subcutaneous Sarcoidosis Occurring along the Superficial Veins of the Forearms: A Distinctive Cutaneous Manifestation Masquerading Venous Tropic Action in the Underlying Systemic Disease?Developing classification criteria for discoid lupus erythematosus: an update from the World Congress of Dermatology 2015 meeting.Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease.High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies.Clonal expansion of Epstein-Barr virus (EBV)-infected γδ T cells in patients with chronic active EBV disease and hydroa vacciniforme-like eruptions.Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis.The wound/burn guidelines - 3: Guidelines for the diagnosis and treatment for diabetic ulcer/gangrene.E- and P-selectins synergistically inhibit bleomycin-induced pulmonary fibrosisPhase-dependent roles of E-selectin during chronic contact hypersensitivity responses.Identification of myocardial damage in systemic sclerosis: a nuclear cardiology approach.Redefining cutaneous lupus erythematosus: a proposed international consensus approach and results of a preliminary questionnaire.A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage.Re-emergence of anti-topoisomerase I antibody with exacerbated development of skin sclerosis in a patient with systemic sclerosis.Anti-topoisomerase I antibody levels as serum markers of skin sclerosis in systemic sclerosis.Chemokine receptors CCR2 and CX3CR1 regulate skin fibrosis in the mouse model of cytokine-induced systemic sclerosis.Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis.
P50
Q24338979-20CE699B-CC08-40E9-952E-1BA5B65100F6Q33297856-43A9FB2E-27E9-46A0-AA76-15DA6CA0086CQ33387310-194E05D7-E5FD-400D-BF5C-20B28B202CCAQ34550972-8AA31B63-CF51-4A72-AA51-8EC873E7F69BQ34661961-78E802E5-045F-49ED-A66E-0463D1395B81Q35091575-0837D510-1E10-44E7-8973-7EEF6637A4D9Q35222002-800C4A3D-C76E-4A9B-9A67-9356AA805439Q35999755-BD357ECD-4E86-44EB-B454-73725E95B141Q36014488-5EFBBC58-3CEA-4EF3-9DE2-D6222D0FD06FQ36123039-66E31EC9-7B2C-44D3-9B29-756CE3A76266Q36342215-5FA7C66E-558A-4F80-95A9-D9AF6E22D014Q36592069-B5EACED1-3C19-4871-8EF2-964CD5986D27Q36691117-5F1014AD-EDD6-409D-BC27-9ACC11B3E24BQ37069130-73D8CEA1-0FF2-40CE-A6A2-8E0DFA186BB7Q37069151-2F2F625A-A890-4079-95D9-5F347E56BC72Q37098552-4D0C5E90-E2DC-407A-BCD4-B3DEABFBB751Q37278463-46ECF96E-61EB-4BD8-B6B4-A821EAD24EFDQ37822871-0B31D3F9-FFDF-425F-A895-59DF672DA1F8Q38006231-D539D6EE-AD96-48CC-8BA8-CE8A14E55454Q38450064-41344633-2E1B-4584-BE85-6794FE097BEBQ38701985-139C1DBD-138C-490C-A185-0A755FD42449Q38807475-FA4A2222-A86A-4C1A-BD75-38D38358EA48Q38981401-435BA851-2C45-489D-868F-1B774969BCE1Q39143651-154A0711-5021-4C05-ADD4-D7633815414FQ39297496-26346C39-A99B-4927-8996-1B42EC6961C1Q39464692-71413490-E15A-4222-B17D-751922AD4110Q40151676-7A5D8F89-C354-42E5-A2B9-56A4EE0EE882Q40277780-40B1C3F3-3068-4911-A9FE-DBDCB5F78C24Q40287055-EB213BEE-CE10-4EBA-9461-850915C9FA89Q40757188-03586638-FAFE-4F2F-9724-FD48EBF5426EQ41090918-010FDAAB-E67A-4F05-B6D3-D0CCCBE3CD73Q41948797-0DBEEC45-77EC-4023-84EF-217FB6244EA2Q42426737-433101D6-2F47-4B28-B11D-30333BDEECF9Q42665120-1D82E4B9-D64C-4544-AEC0-6663EC201BE5Q43251980-58C49860-4464-4075-9C25-B6045AF01ADEQ43257884-BDDC097A-D7FD-41FD-9418-3A7EC18A2AE5Q43280330-D9E0A1B7-AF6F-4A35-80F3-47034DF9A598Q43737924-A8C30956-5DEA-462A-9CA6-EF3C2791C21AQ43749770-B0678F2C-32C1-45BF-9A00-328E30CF0476Q43836174-7BF910B5-5642-434A-B0FE-889C08AC7935
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Minoru Hasegawa
@en
Minoru Hasegawa
@nl
type
label
Minoru Hasegawa
@en
Minoru Hasegawa
@nl
prefLabel
Minoru Hasegawa
@en
Minoru Hasegawa
@nl
P108
P31
P496
0000-0003-3738-2682